ProKidney Corp’s filing revealed that its Add’l Rep. Persons-see Ex.99-1 Control Empresarial de Capital acquired Company’s shares for reported $0.28 million on Apr 22 ’25. In the deal valued at $0.71 per share,387,393 shares were bought. As a result of this transaction, Control Empresarial de Capital now holds 73,842,723 shares worth roughly $59.81 million.
Then, Control Empresarial de Capital bought 25,000 shares, generating $18,690 in total proceeds. Upon buying the shares at $0.75, the Add’l Rep. Persons-see Ex.99-1 now owns 73,455,330 shares.
Before that, Control Empresarial de Capital bought 100,000 shares. ProKidney Corp shares valued at $74,820 were divested by the Add’l Rep. Persons-see Ex.99-1 at a price of $0.75 per share. As a result of the transaction, Control Empresarial de Capital now holds 73,430,330 shares, worth roughly $59.48 million.
JP Morgan initiated its ProKidney Corp [PROK] rating to a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. BofA Securities revised its rating on January 02, 2024. It rated PROK as “a Neutral” which previously was an “a Buy”.
Price Performance Review of PROK
On Monday, ProKidney Corp [NASDAQ:PROK] saw its stock jump 0.22% to $0.81. Over the last five days, the stock has gained 7.79%. ProKidney Corp shares have fallen nearly -52.17% since the year began. Nevertheless, the stocks have fallen -79.38% over the past one year.
How much short interest is there in ProKidney Corp?
A steep rise in short interest was recorded in ProKidney Corp stocks on 2025-04-30, growing by 3.71 million shares to a total of 15.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 11.93 million shares. There was a rise of 23.74%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 25, 2023 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
